Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-NOTA-C60-PEG-cRGD
- Development stage
- Preclinical
- Lead developer
- Soochow University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
64Cu-NOTA-C60-PEG-cRGD is a fullerene-based radiopharmaceutical nanoprobe designed for positron emission tomography (PET) imaging of tumors. It consists of a C60 fullerene core functionalized with polyethylene glycol (PEG) to enhance water solubility and biocompatibility. The platform is conjugated with cyclic Arg-Gly-Asp (cRGD) peptides, which specifically target integrin alpha-V/beta-3, a cell surface receptor highly expressed in various cancers, including glioblastoma, and tumor-associated blood vessels. The compound utilizes the bifunctional chelator NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) to sequester the positron-emitting radioisotope copper-64 (64Cu). This nanoplatform is characterized by its small size (100-120 nm), high tumor uptake, and notably fast renal clearance, making it a promising candidate for safer cancer imaging and potentially theranostic applications.
- Other names
- 64Cu-labeled fullerene-based nanoplatformcRGD-conjugated C60 derivatives
02
Targets
αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on 64Cu-NOTA-C60-PEG-cRGD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-NOTA-C60-PEG-cRGD.